About
Technology
Issues
FAQ
Links
Official Page
Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.